Rallybio Corporation is a biopharmaceutical company focusing on the development and commercialization of transformative therapies for severe and rare diseases. The company's primary purpose is to harness scientific advancements to address unmet medical needs, targeting life-threatening conditions that often lack effective treatment options. Rallybio invests in research and partnerships to explore innovative therapeutic approaches, with an emphasis on speed and efficiency in drug development. The sectors most impacted by Rallybio's work include biotechnology and healthcare, particularly concerning genetic disorders and immunological diseases. As a player within the biopharmaceutical space, the company contributes to the broader healthcare industry's efforts to improve patient outcomes and advance medical science. Rallybio's strategic collaborations with global research institutions and its commitment to scientific excellence underscore its significant role in delivering medical breakthroughs to the market. Launched with a mission to make a difference in patients’ lives, Rallybio embodies the forward momentum of biopharmaceutical innovation.